Buy Adlyxin (Lixisenatide) 100 mcg/ml
Adlyxin is an injectable prescription medicine that may improve blood sugar (glucose) control in adults when used with diet and exercise (similar to the purpose of Trulicity and Victoza). Please note, this is not insulin and is not considered a substitute for insulin. It is not for people with Type 1 diabetes or individuals with diabetic ketoacidosis. This product has not been studied in people with a history of pancreatitis, gastroparesis, and people with diabetes who use short-acting or long-acting insulin. It is currently unknown if Adlyxin is safe and effective in children.
Adlyxin contains lixisenatide, which acts as an agonist for the GLP-1 receptor. The C-terminal amino acid of lixisenatide (position 44) is amidated, forming a peptide containing 44 amino acids. TFigure 1 shows the amino acid sequence. Its molecular weight is 4858.5 and its molecular formula is C215H347N61O65S.
Adlyxin is only part of a complete treatment program that may also include diet, exercise, weight control, blood sugar testing, and special medical care. Follow your doctor’s instructions very closely.
Before Taking Adlyxin
You should not use Adlyxin if you are allergic to lixisenatide or have diabetic ketoacidosis (call your doctor for treatment).
To make sure Adlyxin is safe for you, please notify your doctor if you have pancreatitis or gallstones, problems with digestion, alcoholism, or kidney disease.
Tell your doctor if you are pregnant or breastfeeding.
Follow your doctor’s instructions about using this medicine if you are pregnant or you become pregnant. Controlling diabetes is very important during pregnancy, and having high blood sugar may cause complications in both the mother and the baby.
Adlyxin can make birth control pills less effective. If you take a birth control pill, take it at least 1 hour before or 11 hours after using Adlyxin.
Adlyxin is not approved for use by anyone younger than 18 years old.
Warnings and Precautions
Anaphylaxis and Serious Hypersensitivity Reactions
Lixisenatide-sensitive patients should not be treated with Adlyxin. The patient should stop taking Adlyxin immediately if they experience a hypersensitivity reaction.Patients treated with GLP-1 receptor agonists have experienced acute pancreatitis, including hemorrhagic or necrotizing pancreatitis. Clinical trials of Adlyxin observed 21 cases of pancreatitis in patients treated with Adlyxin and 14 cases in patients treated with the comparator (incidence rate of 21 vs. 17 per 10,000 patient-years). Adlyxin cases included acute pancreatitis (n=3), pancreatitis (n=12), chronic pancreatitis (n=5), and edematous pancreatitis (n=1). Some patients had risk factors for pancreatitis, such as cholelithiasis or alcoholism.
Never Share Adlyxin Pen Between Patients
Even if the needle is changed, Adlyxin pens should never be shared. Blood-borne pathogens can be transmitted through pen-sharing.
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Hypoglycemia may be reduced by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin. Educate patients about hypoglycemia and the signs and symptoms of hypoglycemia if they are taking these concomitant medications.Chronic renal failure and acute kidney injury, which may sometimes require hemodialysis, have been reported post-marketing in patients treated with Adlyxin. In some cases, no underlying renal disease was known. Patients who suffered from nausea, vomiting, diarrhea, or dehydration reported most of the reported events.
Alternate antidiabetic therapies should be considered in the event of worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions, or allergic reactions.
Following treatment with Adlyxin, patients may develop antibodies to lixisenatide. Among lixisenatide-treated patients, a pooled analysis showed that 70% were antibody positive at Week 24. The glycemic response was attenuated in the subset of patients (2.4 %) with the highest antibody concentration (>100 nmol/L). Antibody positive patients had a higher incidence of allergic reactions and injection site reactions.
Patients with renal impairment and patients who report severe gastrointestinal reactions should monitor renal function when initiating or escalating Adlyxin treatment. This medication should not be given to patients with end-stage renal disease.
Acute Kidney Injury
The risks of hypoglycemia, including severe hypoglycemia, are increased for patients who receive Adlyxin and basal insulin or insulin secretagogues (e.g., sulfonylurea). Patients receiving sulfonylurea with or without metformin reported 14.5% of symptomatic hypoglycemia on Adlyxin compared to 10.6% on placebo. 28.3% of patients taking Adlyxin reported symptomatic hypoglycemia compared to 23.0% of patients taking a placebo. In patients receiving basal insulin and sulfonylurea, 47.2% of patients on Adlyxin reported symptoms of hypoglycemia compared to 21.6% on placebo.
Use Adlyxin precisely as prescribed by your doctor.. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Adlyxin is injected under the skin. A healthcare provider may teach you how to use the medication by yourself properly.
Adlyxin is usually injected once per day within 60 minutes (1 hour) before your first meal of the day. Try to use the medicine at the same time each day.
Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you don’t understand all instructions.
Prepare an injection only when you are ready to give it. Do not use if the medicine has changed colors or has particles in it. Call your pharmacist for new medicine.
Your healthcare provider will show you where on your body to inject Adlyxin. Use a different place each time you give an injection. Do not inject into the same place two times in a row.
Never share an injection pen, cartridge, or syringe with another person, even if the needle has been changed. Sharing these devices can allow infections or diseases to pass from one person to another.
Adlyxin can cause serious side effects, such as inflammation of the pancreas (pancreatitis), which may be severe and lead to death. Stop using Adlyxin and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel pain from your waist to your back.
Do not use Adlyxin if you are allergic to lixisenatide or any of the other ingredients in Adlyxin.
Symptoms of severe allergic reaction with Adlyxin may include swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
Your doctor may prescribe a glucagon injection kit in case you have severe hypoglycemia. Be sure your family or close friends know how to give you this injection in an emergency.
Adlyxin can slow your digestion, and it may take longer for your body to absorb any medicines you take by mouth.
-If you also take acetaminophen (Tylenol), take it at least 1 hour before using Adlyxin.
-If you also take an antibiotic, take it at least 1 hour before you use Adlyxin.
-If you also take a birth control pill, take it at least 1 hour before or 11 hours after using this medicine.
Other drugs may interact with lixisenatide, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Wait until your next meal and use the medicine within 1 hour before you eat. Then go back to your regular injection schedule the next day. Do not use two doses at one time.
If you overdose on Adlyxin please seek medical attention immediately, as this can lead to poisoning and death.
In patients with mild renal impairment no dose adjustment is required but close monitoring for Adlyxin related adverse reactions and for changes in renal function is recommended because a higher incidence of hypoglycemia, nausea and vomiting was observed in these patients.
In a cardiovascular outcome study, 655 (22%) lixisenatide treated patients had moderate renal impairment (eGFR: 30 to less than 60 mL/min/1.73 m2). Patients with moderate renal impairment do not require dosing adjustments, but close monitoring is recommended for adverse reactions related to Adlyxin, as these reactions may cause dehydration and acute kidney failure and worsen chronic renal failure.
Adlyxin has minimal clinical experience in patients with severe renal impairment as only 5 patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) were exposed to it in all controlled studies. These patients had higher levels of lixisenatide exposure. Adlyxin should be carefully monitored for gastrointestinal adverse reactions and alterations in renal function in patients with significant renal impairment.
Adlyxin has no therapeutic experience in patients with end-stage renal disease (eGFR 15 mL/min/1.73 m2), and it is not recommended for patients with this condition.
Animal studies have shown reproductive toxicity. Studies in pregnant rats and rabbits at doses of 1 and 6 times the recommended human dose, respectively, were associated with visceral closure and skeletal defects. There are no controlled data in human pregnancy.
In humans, poorly controlled diabetes during pregnancy increases the fetal risk for significant congenital disabilities, stillbirth, and macrosomia-related mortality.
AU TGA pregnancy category B3: Drugs that have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy.
There is insufficient available data in pregnant women to inform a drug-associated risk of significant congenital disabilities and miscarriage.
Adlyxin is not known to be present in human milk, nor are the effects of Adlyxin on the breastfed infant or milk production. Rat milk does contain lixisenatide. As well as breastfeeding’s developmental and health benefits, the mother’s clinical need for lixisenatide and the baby’s potential adverse effects from lixisenatide or from the maternal condition should be considered.
Storing unopened (not in use) Adlyxin: Refrigerate and protect from light. Take the injection pen out of the refrigerator and allow it to reach room temperature before using it.
Do not freeze, and throw away the medicine if it has been frozen.
Storing opened (in use) Adlyxin: Store at room temperature in the original package with the pen cap attached. Do not store with a needle attached.
The prefilled injection pen contains 14 pre-set doses for daily use. Throw the pen away after 14 days, even if there is still medicine left inside.
Put the cap back on your Adlyxin pen before throwing it away (getting rid of it). Immediately after use, dispose of the used Adlyxin pen in a sharps disposal container approved by the FDA. In your household trash, do not dispose of Adlyxin pens or loose needles. In the absence of an FDA-cleared sharps disposal container, you may use a household container that is: made of heavy-duty plastic, sealed with a tight-fitting, puncture-resistant lid, upright and stable during use, leak-resistant, and properly labeled to alert the user that the container contains hazardous waste.